Health startup Casana has launched a toilet seat embedded with AI-powered sensors that passively track blood pressure, heart rate, and other vitals, betting on a daily routine most people never skip.
The FDA has cleared Brainomix's stroke-imaging AI to read non-contrast CT scans, a format used in roughly 60% of U.S. stroke imaging, extending fast triage software far beyond its original contrast-scan clearance.
The 2026 State of Nursing Survey finds only 22% of nurses trust AI tools for patient care and 60% say they were never adequately trained on the technology, though trust nearly doubles among nurses who had a say in selecting the tools.
Ardent Health says its clinicians have now completed 1 million patient encounters supported by Ambience Healthcare's ambient AI documentation platform, reporting a 45% cut in charting time and five hours saved per clinician weekly.
Cedars-Sinai has embedded OpenEvidence's AI clinical reference platform directly inside Epic, giving physicians, nurses, and pharmacists patient-context-aware answers grounded in medical literature at the point of care.
An Emory University study of 2,784 U.S. hospitals found that 62.6% have adopted ambient AI documentation tools, but adoption is concentrated in wealthier, larger, urban hospitals, raising concerns about a widening care gap.
PathAI received FDA Breakthrough Device Designation for PathAssist Derm, an AI tool aimed at dermatopathology, a specialty where diagnostic agreement between pathologists falls below 50% on the hardest skin lesion cases.
Leica Biosystems received FDA clearance for Aperio iQC DX, the first standalone AI quality-control tool for clinical digital pathology, which caught up to 24% more slide artifacts than histotechnicians in a Heidelberg University study.
British startup C the Signs is seeking first-of-its-kind FDA De Novo clearance for an AI tool that mines existing medical records to flag cancer risk, after helping identify 75,000 cancer patients across the UK's NHS.
Alibaba DAMO Academy's PANDA AI model, which detects early pancreatic cancer on routine CT scans with 92.9% sensitivity, has received FDA Breakthrough Device Designation after screening more than 70,000 patients in China.